Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)

Trial Profile

GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 17 May 2019

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Antithrombotics
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GLORIA-AF
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2019 Planned End Date changed from 14 Jan 2020 to 31 Dec 2019.
    • 28 Feb 2019 Planned primary completion date changed from 14 Jan 2020 to 31 Dec 2019.
    • 29 Aug 2018 Results (n=21248; see profiles: 209508 and 222289) presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top